Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Insulin Sensitizer Has Anti-inflammatory Effect in Diabetics

17.06.2002


Study has implications for lowering heart-disease risk in Type 2 diabetes patients



A drug used widely as an insulin sensitizer appears also to have a significant anti-inflammatory effect in diabetics, a property that could make it useful in helping to prevent heart disease in these patients, a study by endocrinologists at the University at Buffalo has found.

Results of the research, involving the drug rosiglitazone, were presented here today (June 15, 2002) at the annual meeting of the American Diabetes Association. Rosiglitazone is sold under the brand name Avandia(r).


UB endocrinologists, led by Paresh Dandona, M.D., professor of medicine and head of the Division of Endocrinology in the UB School of Medicine and Biomedical Sciences, have been studying the anti-inflammatory properties of insulin and insulin sensitizers and their potential use in treatment and prevention of atherosclerosis, one of the leading causes of heart attacks.

Atherosclerosis, or hardening of the arteries, begins as an inflammation of the blood-vessel wall. Persons with diabetes are at increased risk of developing atherosclerosis and heart disease. Dandona’s lab has shown in research with a small group of obese non-diabetic volunteers that rosiglitazone decreased the levels of oxygen free radicals which can begin the inflammation cascade by injuring blood-vessel linings. The drug also decreased the levels of several blood markers of inflammation.

The current study involved 11 obese patients with Type 2 diabetes. In this disease, also referred to as adult-onset diabetes, the body produces adequate amounts of insulin, but cells don’t respond to its action. Rosiglitazone is prescribed to break down this resistance to insulin.

Researchers collected blood samples from the diabetic volunteers and started them on a six-week course of daily rosiglitazone. They repeated the blood sampling four times during the six weeks of treatment and again at 12 weeks, and analyzed the samples for concentration of three inflammatory markers and for the presence of oxygen free radicals.

Results showed that the drug exerted a "profound" suppressive effect on free radicals and on other mediators of inflammation in the blood.

"The ability to reduce inflammation is crucial for preventing atherosclerosis and cardiovascular disease, " said Dandona. "Previous data demonstrated rosiglitazone’s effectiveness in reducing key markers of cardiovascular disease in patients at risk for diabetes. This study in people with diabetes further underscores rosiglitazone’s potential to have a cardio-protective effect."

Analysis of blood samples showed that at six weeks, free radical generation had dropped about 34 percent from baseline. Concentration of the inflammatory markers plasma monocyte chemoattractant protein-1 (MCP-1) and C-reactive protein (CRP) fell by 25 percent and 30 percent, respectively, at six weeks. At 12 weeks inflammatory markers had returned to baseline.

Rosiglitazone also improved vascular reactivity - the ability of vessels to expand and contract in response to changes in blood flow -- which is crucial for maintaining healthy blood pressure and blood flow to vital organs.

Also involved in the study, all from UB’s department of Medicine, were Priya Mohanty, M.D.; Ahmad Alijada, Ph.D.; Husam Ghanim; Deborah Hofmeyer; Devjit Tripathy, M.D., and Sandeep Dhindsa, M.D.

The study was funded by GlaxoSmithKline, manufacturer of Avandia.

Lois Baker | EurekAlert

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Electrical 'switch' in brain's capillary network monitors activity and controls blood flow

27.03.2017 | Health and Medicine

Clock stars: Astrocytes keep time for brain, behavior

27.03.2017 | Life Sciences

Sun's impact on climate change quantified for first time

27.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>